Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma.

Analyzing molecular biomarkers using blood is an important approach for clinical assessment of malignant glioma. We investigated a molecular proteomic biomarker-based approach for glioblastoma using patients' blood samples. The expression levels of a list of candidate proteins were quantified in plasma and serum samples from two different cohorts of patients with malignant glioma and normal controls. The biological function was studied for one of the identified markers. Additionally, the prognostic significance of protein marker expression was measured by survival analysis. As a result, protein biomarkers associated with malignant glioma were identified from the blood specimens and five of the protein biomarkers were common to both cohorts. Immunohistochemical analysis demonstrated that many of the protein biomarkers identified in peripheral blood specimens were expressed in malignant gliomas. Staining levels for one of the biomarkers, MIP-1α, was found to correlate with WHO grade among invasive gliomas, and we demonstrate that MIP-1α promotes human glioblastoma cell proliferation and migration. Additionally, four prognostic protein biomarkers were identified. In conclusion, we demonstrate that both peripheral blood plasma and serum specimens are highly valuable and complementary to each other in the quest for protein biomarkers of malignant glioma. Sets of novel protein biomarkers were identified that may aid in the diagnosis and prognosis of patients with malignant glioma.

[1]  M. K. Cooper,et al.  Activation of the Hedgehog pathway in pilocytic astrocytomas , 2010, Neuro-oncology.

[2]  P. Wen,et al.  Antiangiogenic therapies for high-grade glioma , 2009, Nature Reviews Neurology.

[3]  Wei Zhang,et al.  Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. , 2009, Neuro-oncology.

[4]  Jinghua Zhao,et al.  Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian Cancer , 2009, PloS one.

[5]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[6]  A. Ray,et al.  Emerging functions of c-kit and its ligand stem cell factor in dendritic cells , 2008, Cell cycle.

[7]  Ignacio A. Romero,et al.  Chemokine production and chemokine receptor expression by human glioma cells: Role of CXCL10 in tumour cell proliferation , 2008, Journal of Neuroimmunology.

[8]  R. Béliveau,et al.  Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2 , 2008, Journal of neurochemistry.

[9]  D. Zurakowski,et al.  Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy , 2008, Clinical Cancer Research.

[10]  D. Brat,et al.  RESEARCH ARTICLE: Intravascular Thrombosis in Central Nervous System Malignancies: A Potential Role in Astrocytoma Progression to Glioblastoma , 2007, Brain pathology.

[11]  L. Rosengren,et al.  Serum levels of glial fibrillary acidic protein correlate to tumour volume of high‐grade gliomas , 2007, Acta neurologica Scandinavica.

[12]  E. Gerstner,et al.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Divella,et al.  Epidermal Growth Factor Receptor Serum Levels and Prognostic Value in Malignant Gliomas , 2007, Tumori.

[14]  K. Dietz,et al.  Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors , 2007, Archivum Immunologiae et Therapiae Experimentalis.

[15]  J. Iłżecka,et al.  APRIL is increased in serum of patients with brain glioblastoma multiforme. , 2006, European cytokine network.

[16]  Wei Zheng,et al.  Immunohistochemical Expressions of Ki-67, Cyclin D1, β-Catenin, Cyclooxygenase-2, and Epidermal Growth Factor Receptor in Human Colorectal Adenoma: A Validation Study of Tissue Microarrays , 2006, Cancer Epidemiology Biomarkers & Prevention.

[17]  D. Crooks,et al.  Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. , 2006, Oncology reports.

[18]  K. Aldape,et al.  Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. , 2006, Cancer research.

[19]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[20]  A. Teramoto,et al.  Growth hormone enhances natural killer cell activity against glioma. , 2005, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[21]  S. Demaria,et al.  Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain , 2005, Laboratory Investigation.

[22]  E. Terpos,et al.  Significance of macrophage inflammatory protein-1 alpha (MIP-1α) in multiple myeloma , 2005, Leukemia & lymphoma.

[23]  M. Emi,et al.  Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth , 2004, Journal of Neuro-Oncology.

[24]  E. von Stebut,et al.  Macrophage inflammatory protein-1. , 2004, The international journal of biochemistry & cell biology.

[25]  C. Capobianco,et al.  Involvement of metalloprotease-2 in the development of human brain microvessels , 2004, Histochemistry and Cell Biology.

[26]  B. Dörken,et al.  Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. , 2003, Blood.

[27]  B. Su,et al.  Tissue factor expression and angiogenesis in human glioma. , 2002, Clinical biochemistry.

[28]  M. Fukuzawa,et al.  Decreased Production of Interleukin-12 and Type 2 Immune Responses Are Marked in Cachectic Patients with Colorectal and Gastric Cancer , 2002, Journal of clinical gastroenterology.

[29]  M. Duffy.  CA 19-9 as a Marker for Gastrointestinal Cancers: A Review , 1998, Annals of clinical biochemistry.

[30]  H. Abe,et al.  Human astrocytoma cells are capable of producing macrophage inflammatory protein-1Β , 1998, Journal of Neuro-Oncology.

[31]  G. Nicolson,et al.  Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro , 1997, Clinical & Experimental Metastasis.

[32]  M. Yamamoto,et al.  Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. , 1997, Cancer research.

[33]  J. Becker,et al.  Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. , 1995, Melanoma research.

[34]  E. Thiel,et al.  Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. , 1992, Cancer research.

[35]  O. Kalita,et al.  Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. , 2009, Neoplasma.

[36]  U. Yamashita,et al.  Regulation of macrophage-derived chemokine (MDC, CCL22) production. , 2002, Critical reviews in immunology.

[37]  The influence of 8-Cl-cAMP on tumor marker CA19.9 on experimental glioma in rats , 2001 .